Department of Psychiatry (AJF, BHM, ANV), University of Toronto, ON, Canada; Centre for Mental Health, University Health Network (AJF), Toronto, ON, Canada.
University of Massachusetts Medical School and UMass Memorial Health Care (AJR), Worcester, MA.
Am J Geriatr Psychiatry. 2021 Jul;29(7):645-654. doi: 10.1016/j.jagp.2020.11.003. Epub 2020 Nov 15.
To examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.
Two hundred and sixty-nine men and women aged 18-85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.
Participants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18-59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.
Older patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not.
研究在使用舍曲林联合奥氮平治疗精神病性抑郁症的扩展疗程中,年龄较大与年龄较小对人体测量和代谢指标变化的影响。
269 名年龄在 18-85 岁之间、患有精神病性抑郁症发作的男性和女性患者接受了为期 12 周的舍曲林联合奥氮平开放标签治疗。在 8 周稳定期后仍处于缓解期的患者有资格参加一项为期 36 周的随机对照试验(RCT),该试验比较了舍曲林联合奥氮平和舍曲林联合安慰剂的疗效和耐受性。在研究的急性、稳定和随机阶段,定期测量体重、腰围和血浆脂质、血糖、HbA1c 和胰岛素。使用线性混合模型分析人体测量和代谢指标的轨迹。
与 18-59 岁的参与者相比,年龄在 60 岁或以上的参与者在研究的联合急性和稳定阶段体重增加较少,胆固醇增加较少。在急性-稳定期结束时,年龄较大的参与者的平均体重比发病前减轻了 6.5 磅,而年龄较小的参与者的平均体重比发病前增加了 17.9 磅。在 RCT 中,体重的治疗和年龄组之间存在显著的交互作用,但在每个治疗组内比较年龄组的事后检验没有统计学意义。年轻和年长参与者在血糖指标方面没有显著差异。
与年轻患者相比,在使用舍曲林联合奥氮平治疗精神病性抑郁症的急性和稳定期,年龄较大的患者体重和总胆固醇增加较少。在年龄较大的组中,急性和稳定期体重增加似乎是指数发作期间体重减轻的部分恢复,而年轻患者的体重增加则不是。